0.9046
1.40%
-0.0139
전일 마감가:
$0.9185
열려 있는:
$0.9138
하루 거래량:
1.90M
Relative Volume:
0.53
시가총액:
$273.29M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-2.4449
EPS:
-0.37
순현금흐름:
$-72.53M
1주 성능:
-9.44%
1개월 성능:
-3.50%
6개월 성능:
-51.05%
1년 성능:
+134.01%
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
OCGN | 0.9047 | 273.29M | 0 | -63.08M | -72.53M | -0.37 |
VRTX | 448.45 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 747.78 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.26 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.71 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-15 | 개시 | Maxim Group | Buy |
2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
2022-08-23 | 개시 | Mizuho | Buy |
2022-06-15 | 재개 | ROTH Capital | Buy |
2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
2021-07-26 | 개시 | Noble Capital Markets | Outperform |
2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen Announces European Medicines Agency Grants Orphan - GlobeNewswire
Ocugen reports positive data for OCU400, OCU410 - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen announces EMA granted orphan medicinal product designation for OCU410ST - TipRanks
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MSN
Ocugen's Eye Disease Drug Shows 84% Lesion Reduction, Receives EMA Orphan Status | OCGN Stock News - StockTitan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy - Ophthalmology Times
Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial - TipRanks
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Ocugen Announces Compelling Preliminary Data for OCU410—a - GlobeNewswire
Ocugen's Eye Treatment Shows 21% Disease Slowdown in Phase 1 Trial Data | OCGN Stock News - StockTitan
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
OCGN Stock: Can New Leadership Save This Biotech Company? - TipRanks
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Appoints Ramesh Ramachandran as Financial Officer - TipRanks
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Nasdaq Health Care Index (IXHC) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Ocugen: Q3 Earnings Snapshot - New Haven Register
Ocugen, Inc. (OCGN) Quarterly 10-Q Report - Quartzy
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Ocugen Inc. - Quantisnow
HC Wainwright Has Pessimistic View of Ocugen FY2024 Earnings - MarketBeat
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Present Innovations at Nasdaq Clinical Showcase - TipRanks
Navigating 4 Analyst Ratings For Ocugen - Benzinga
Ocugen (NASDAQ:OCGN) Given Buy Rating at HC Wainwright - MarketBeat
Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
Earnings call: Ocugen outlines progress in ophthalmology trials, financials - Investing.com
Earnings call: Ocugen outlines progress in ophthalmology trials, financials By Investing.com - Investing.com Australia
Ocugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen: Progress in Gene Therapy and Financial Outlook - TipRanks
Ocugen (OCGN) Q3 2024 Earnings Call Transcript - The Motley Fool
OCGN Earnings: Ocugen’s Q3 Results Disappoint - TipRanks
Ocugen receives $30M credit facility to fund, allocate resources across company - Pennsylvania Business Report
Ocugen reports Q3 revenue $1.136M, consensus $300,000 - TipRanks
Ocugen Provides Business Update with Third Quarter 2024 Financial Results - Ocugen
Ocugen Secures $65M Financing, Extends Runway to 2026 as Gene Therapy Trials Advance | OCGN Stock News - StockTitan
Ocugen (NASDAQ:OCGN) soars 19% this week, taking one-year gains to 193% - Simply Wall St
A Preview Of Ocugen's Earnings - Benzinga
Ocugen Secures $30 Million In Debt Funding - citybiz
Ocugen Secures $30 Million in Debt Funding - Ocugen
Ocugen, Inc. Secures $30 Million in Debt Funding - Marketscreener.com
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):